AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1.-34. (Canceled).

- 35. (New) A process for isolating maytansinol from a mixture containing unreduced and over-reduced maytansinoids by separating the maytansinol by normal-phase high performance liquid chromatography (HPLC) on a chemically modified silica stationary phase.
 - **36.** (New) Maytansinol prepared by the process of claim 35.
- 37. (New) A cell-binding agent maytansinoid complex prepared by converting maytansinol prepared by the process of claim 35 into the cell-binding agent maytansinoid complex.
- 38. (New) The cell binding agent of Claim 37, wherein the cell-binding agent is an antibody.
- **39.** (New) The process of claim 35, wherein the chemically modified silica is cyanobonded silica.

- **40.** (New) Purified maytansinol prepared by the process of claim 35, wherein the purity of maytansinol is at least 90%.
- 41. (New) The process of claim 35, further comprising converting the maytansinol prepared by the process into a cell-binding agent maytansinoid complex.
- **42. (New)** A process for isolating maytansinol from a mixture containing unreduced and over-reduced maytansinoids by separating the maytansinol by large-scale preparative normal-phase high performance liquid chromatography (HPLC) on a chemically modified silica stationary phase.
 - 43. (New) Maytansinol prepared by the process of claim 42.
- **44.** (New) A cell-binding agent maytansinoid complex prepared by converting maytansinol prepared by the process of claim 42 into the cell-binding agent maytansinoid complex.
- **45.** (New) The cell-binding agent of claim 44 wherein the cell-binding agent is an antibody.

Preliminary Amendment Divisional of U.S. Appln. No. 10/410,143 Attorney Docket No.: A8707

- **46.** (New) The process of claim 42 wherein the chemically modified silica is cyanobonded silica.
- **47.** (New) Purified maytansinol prepared by the process of claim 42 wherein the purity of the maytansinol is at least 90%.
- **48.** (New) The process of claim 42 further comprising converting the maytansinol prepared by the process into a cell-binding agent maytansinoid complex.